Kevin Mills, PhD has joined the National Hemophilia Foundation as chief scientific officer.
A graduate of University of Colorado Boulder, MIT, and Harvard Medical School, Dr. Mills will be responsible for overseeing NHF’s research strategy, including developing and expanding the foundation’s research capabilities, and setting research goals.
Dr. Mills brings more than 20 years of experience in biotechnology, hematology, and oncology to the role. In 2005, Dr. Mills joined the faculty at the Jackson Laboratory in Bar Harbor, Maine and led a laboratory focused on the biology of DNA repair in hematology and oncology. In 2012, he co-founded Cyteir Therapeutics, a biotechnology company developing and commercializing new therapies targeting DNA repair pathways. As Cyteir’s chief scientific officer, he led the team that brought a first-in-class RAD51 inhibitor into clinical trials. Dr. Mills subsequently joined Civetta Therapeutics as chief scientific officer.
“NHF has renewed its focus on research to achieve a vision of a world without inheritable blood disorders,” said NHF president and CEO, Leonard A. Valentino, MD. “Dr. Mills’ experience in transformative research, combined with our commitment to putting the patient at the center of our research endeavors, will allow NHF to have a significant role supporting work that can have a generational impact on people who live with inheritable blood disorders.”
To learn more about NHF’s commitment to research, visit https://www.hemophilia.org/research.
